Physician profile
Muhammad Sarki
NPI 1730436817
$15,161.76
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $95.34 · 2023: $370 · 2024: $1,085 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $3,671 · Education: $10.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $11,224.95 |
| Food and Beverage | $3,670.86 |
| Education | $10.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,421.30 | 2025 | Hawkone, Turbohawk |
| Reflow Medical INC | $668.12 | 2024-2025 | |
| Abbott Laboratories | $600.50 | 2024-2025 | Mitraclip, Aveir, Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $278.47 | 2024-2025 | |
| Boston Scientific Corporation | $246.69 | 2023-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $201.16 | 2023-2025 | Camzyos, Eliquis |
| Philips North America LLC | $191.09 | 2020-2025 | Event, (6554) Peripheral Vascular Undivided, Diagnostic Ecg Service |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.98 | 2024 | Jardiance |
| Amgen INC. | $143.70 | 2023-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $136.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.68 | 2019-2025 | Farxiga |
| Cardiovascular Systems INC. | $105.49 | 2019-2023 | Diamondback Peripheral |
| Haemonetics Corporation | $101.56 | 2023 | |
| Cvrx, INC. | $94.27 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $92.84 | 2023-2025 | Verquvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $78.08 | 2023-2025 | Nexletol |
| Pfizer INC. | $72.29 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $62.77 | 2024 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.06 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $51.46 | 2025 | Onpattro |
| Bridgebio Pharma, INC. | $44.77 | 2025 | Attruby |
| Heartflow, INC. | $37.03 | 2025 | |
| Abiomed | $36.30 | 2020 | |
| Baxter Healthcare | $28.34 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| W. L. Gore & Associates, INC. | $25.27 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Biosense Webster, INC. | $23.74 | 2023 | Na |
| Smith+Nephew, INC. | $21.94 | 2025 | Collagenase Santyl |
| Novo Nordisk INC | $21.56 | 2025 | Wegovy |
| Stryker Corporation | $20.06 | 2025 | Artix Mt |
| Lexicon Pharmaceuticals, INC. | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Sarki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.